This suggests that SCN5A-related DCM may, in some cases, be secondary to electrical dysfunction rather than solely a primary structural cardiomyopathy, although no studies have clearly described the response of SCN5A DCM to heart failure therapy. This evidence concerns the gene SCN5A and cardiomyopathy.